breast cancer - HR positive | |
es-BC - HR-positive - 1st line (L1) | |
taselisib based treatment | |
taselisib plus letrozole | LORELEI |
Study type:
delta: difference in rate or median (if available)
- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy -